ascendis pharma glp-1 Novo inks deal to develop long-acting GLP-1, other metabolic drugs effect free approach to reducing appetite ascendis pharma glp-1 receptor agonist

The reduced dose, not the reduced frequency, is what defines microdosing

Which categories will see reduced frequency, and which will see trade-up behavior

Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin

Along with a significant pool of preclinical data on the effect of GLP-1RAs (including exendin-4) on PD models in experimental animals, showing a decrease in the loss of dopaminergic neurons and accumulation of -synuclein in the brain, a decrease in mitochondrial dysfunction and expression of pro-inflammatory mediators such as tumor necrosis factor (TNF)- and interleukin IL-1 [61], promising data from clinical studies on the use of GLP-1RAs in PD have been obtained [62]